Emerging antibody-drug conjugate (ADC) therapies: perspectives from the global patent landscape

Tong Wu, Baijun Liu, Jiayu Jin, Yajie Zhou, Hongmei Yuan

Open source

DOI
10.3389/fphar.2026.1853273
Published
2026-10-22
Container
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1853273,
  title = {Emerging antibody-drug conjugate (ADC) therapies: perspectives from the global patent landscape},
  author = {Tong Wu and Baijun Liu and Jiayu Jin and Yajie Zhou and Hongmei Yuan},
  year = {2026},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2026.1853273},
  url = {https://doi.org/10.3389/fphar.2026.1853273}
}

RIS

TY  - JOUR
TI  - Emerging antibody-drug conjugate (ADC) therapies: perspectives from the global patent landscape
AU  - Tong Wu
AU  - Baijun Liu
AU  - Jiayu Jin
AU  - Yajie Zhou
AU  - Hongmei Yuan
PY  - 2026
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1853273
UR  - https://doi.org/10.3389/fphar.2026.1853273
ER  - 

APA

Wu, T., Liu, B., Jin, J., Zhou, Y., & Yuan, H. (2026). Emerging antibody-drug conjugate (ADC) therapies: perspectives from the global patent landscape. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1853273

Source records